Regulus Therapeutics Inc RGLS

NAS: RGLS | ISIN: US75915K2006   26/04/2024
2,420 USD (+6,61%)
(+6,61%)   26/04/2024
Grafiek Regulus Therapeutics Inc Grafiek Regulus Therapeutics Inc

Regulus Therapeutics Inc in het nieuws

21 maart 2024 · Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates · Persbericht

12 maart 2024 · Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity · Persbericht

12 maart 2024 · Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

2 januari 2024 · Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

9 november 2023 · Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates · Persbericht

2 november 2023 · Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

19 oktober 2023 · Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

20 september 2023 · Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

13 september 2023 · Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) · Persbericht

5 september 2023 · Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences · Persbericht

Profiel Regulus Therapeutics Inc

Fabricage van farmaceutische preparaten
Farmaceutische producten: Andere
Gezondheidstechnologie
Productie

Website: www.regulusrx.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

CEO: Joseph Hagan

Werknemers: 47

Aandelen Regulus Therapeutics Inc

Beurswaarde: 158,43 miljoen USD

Effecten: 65,47 miljoen

Beta: 1,69

Mijn selecties